Trials / Completed
CompletedNCT06172426
Incidence of Psoriatic Arthritis Among Psoriasis Patients Newly Initiated With Secukinumab in a US Claims Database and a UK Registry
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,171 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This was a retrospective cohort study to assess the incidence rate of psoriatic arthritis (PsA) among psoriasis (PsO) patients newly initiated on secukinumab or any biologics/apremilast (small molecule). The analysis was performed in two databases, IBM® MarketScan® database: Commercial Claims and Encounters (CCAE) and Medicare Supplemental Beneficiaries (MDCR) from 01 January 2010 to 30 June 2021 and BADBIR from 01 January 2016 to 01 September 2021.
Conditions
Timeline
- Start date
- 2022-11-17
- Primary completion
- 2022-12-07
- Completion
- 2022-12-07
- First posted
- 2023-12-15
- Last updated
- 2023-12-15
Locations
1 site across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT06172426. Inclusion in this directory is not an endorsement.